Multiple Mitochondrial Dysfunctions Syndrome 4 (MMDS4) Cell Models for Research

Multiple Mitochondrial Dysfunctions Syndrome 4 (MMDS4) is an ultra-rare autosomal recessive disorder caused by mutations in the IBA57 gene. The exact prevalence is unknown, but fewer than 50 cases have been reported worldwide (WHO, 2023). The disease typically presents in infancy or early childhood with severe neurological symptoms, including developmental regression, hypotonia, seizures, and spasticity. Most affected individuals do not survive beyond early childhood, with a median survival of approximately 3 years (NCI, 2023). The clinical impact is profound, with no effective disease-modifying therapies currently available. The rarity and severity of MMDS4 underscore the urgent need for research models to understand its pathogenesis and develop therapeutic interventions.

MMDS4 serves as an excellent model for studying mitochondrial dysfunction, iron-sulfur cluster biogenesis, and neurodegeneration. The disease is caused by defects in the IBA57 protein, which is essential for the assembly of mitochondrial iron-sulfur clusters. These clusters are critical for the function of multiple enzymes, including those involved in the electron transport chain and amino acid metabolism. Public datasets, such as those from the NCBI Gene and ClinVar, provide detailed information on pathogenic variants. Open questions include the precise molecular mechanisms linking IBA57 deficiency to neuronal death and the potential for targeted therapies. Gene-edited cell models, such as IBA57 knockout cell lines, are invaluable for dissecting these pathways and screening for therapeutic compounds.

Although MMDS4 is not a cancer, the underlying pathways are relevant to mitochondrial dysfunction and neurodegeneration. The major pathways include:

• • Iron-Sulfur Cluster Biogenesis: IBA57 is involved in the assembly of [4Fe-4S] clusters. Defects lead to impaired activity of mitochondrial enzymes such as aconitase and complex I and II of the electron transport chain.
• • Mitochondrial Energy Metabolism: Reduced ATP production due to defective oxidative phosphorylation leads to cellular energy crisis, particularly affecting high-energy-demand tissues like the brain.
• • Oxidative Stress: Impaired iron-sulfur cluster biogenesis can lead to mitochondrial iron accumulation and increased reactive oxygen species (ROS), causing oxidative damage to lipids, proteins, and DNA.
• • Apoptosis and Neurodegeneration: Mitochondrial dysfunction triggers intrinsic apoptotic pathways, leading to neuronal cell death and progressive neurodegeneration.

The table below summarizes the most common genetic alterations in MMDS4, based on data from ClinVar and the NCBI Gene database.

The deregulated signaling networks in MMDS4 include:

• • Mitochondrial Retrograde Signaling: Mitochondrial stress activates signaling pathways that communicate with the nucleus, including the AMPK pathway and the integrated stress response (ISR). Key nodes include AMPK, ATF4, and CHOP.
• • Apoptotic Signaling: Mitochondrial outer membrane permeabilization leads to cytochrome c release and activation of caspases. Key nodes include BAX, BAK, and caspase-3.
• • Oxidative Stress Response: Increased ROS activates the Nrf2 pathway, leading to upregulation of antioxidant genes. Key nodes include Nrf2, KEAP1, and HO-1.
• • Neuroinflammation: Microglial activation and release of pro-inflammatory cytokines, such as TNF-alpha and IL-6, contribute to neuronal damage. Key nodes include NF-kB and NLRP3.

Common cell lines used for MMDS4 research include patient-derived fibroblasts and induced pluripotent stem cells (iPSCs). The table below lists some examples.

Organoids, particularly brain organoids, offer a more physiologically relevant 3D model to study neuronal development and dysfunction. They can be generated from patient iPSCs and recapitulate key features of MMDS4, such as mitochondrial dysfunction and neuronal death.

Animal models for MMDS4 are limited due to the rarity of the disease. However, the following models have been used:

• • IBA57 Knockout Mouse: A constitutive knockout mouse model exhibits embryonic lethality, indicating the essential role of IBA57 in development. Heterozygous mice show mild mitochondrial dysfunction.
• • Conditional Knockout Mouse: Tissue-specific knockouts, such as neuronal-specific IBA57 knockout, have been generated to study the role of IBA57 in the brain.
• • Zebrafish Models: Morpholino-based knockdown of iba57 in zebrafish recapitulates mitochondrial dysfunction and neurological phenotypes.
• • Patient-Derived Xenograft (PDX): Not applicable for MMDS4 as it is not a cancer, but patient-derived fibroblasts can be used for in vivo studies in immunodeficient mice.

CRISPR-based gene editing has enabled the generation of isogenic cell lines with precise mutations in IBA57. These models are essential for studying the functional consequences of specific variants and for drug screening. Examples include:

• • IBA57 Knockout Cell Lines: Using CRISPR/Cas9, IBA57 can be knocked out in cell lines such as HEK293T or SH-SY5Y. These cells exhibit mitochondrial dysfunction, reduced ATP production, and increased ROS levels.
• • IBA57 Point Mutation Knock-In Lines: Specific patient mutations, such as p.Tyr164Cys, can be introduced into cells to create disease-relevant models. These lines are valuable for studying the impact of specific variants on protein function.
• • Reporter Cell Lines: Cells with a mitochondrial reporter, such as MitoTimer or MitoSOX, can be engineered to monitor mitochondrial health in real-time.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing consistent and validated tools. These models are generated using advanced CRISPR technologies and are quality-controlled to ensure high specificity and minimal off-target effects.

Gene-edited cells are used to validate the function of IBA57 and other genes involved in mitochondrial iron-sulfur cluster biogenesis. For example:

• • Knockout Studies: IBA57 knockout cells can be used to study the downstream effects on mitochondrial enzymes, such as aconitase and complex I/II activity.
• • Rescue Experiments: Introducing wild-type IBA57 into knockout cells can confirm the specificity of the phenotype.
• • Variant Characterization: Knock-in cells with patient-specific mutations can be used to assess the impact of each variant on protein stability, localization, and function.

Isogenic cell pairs (wild-type vs. IBA57 knockout) are ideal for high-throughput drug screening to identify compounds that rescue mitochondrial dysfunction. Applications include:

• • Phenotypic Screening: Screening libraries of small molecules for their ability to restore ATP levels or reduce ROS in IBA57-deficient cells.
• • Target Validation: Confirming that a drug candidate acts on the IBA57 pathway by testing its effect on isogenic pairs.
• • Resistance Mechanisms: Studying how cells adapt to chronic mitochondrial dysfunction, which may inform on potential resistance mechanisms to therapies.

CRISPR-based screens can identify genes that, when knocked out, are synthetically lethal with IBA57 deficiency. This approach can reveal novel therapeutic targets and biomarkers. For example:

• • Synthetic Lethality Screens: Using CRISPR libraries to knock out each gene in IBA57-deficient cells and identify those that cause cell death, revealing potential drug targets.
• • Biomarker Identification: Comparing the transcriptome and proteome of IBA57 knockout vs. wild-type cells can identify differentially expressed genes and proteins that may serve as biomarkers for disease progression or treatment response.

The following public databases provide valuable data for MMDS4 research: